We discuss a phase I study (CALM) of an allogeneic anti-CD19 CART-T product, using aprepitant (?) for pruritis from EGFR TKIs, and the widely discussed NordICC study on colonoscopy screening.CALM: https://doi.org/10.1016/S2352-3026(22)00245-9Aprepitant vs. desloratidine: https://doi.org/10.1002/cncr.34474NordICC: https://www.nejm.org/doi/full/10.1056/NEJMoa2208375NordICC editorial: https://www.nejm.org/doi/full/10.1056/NEJMe2211595